Cytomegalovirus Infection — Patent Landscape
1
Approved drugs
8
Active US patents
27/100
Avg vulnerability
$978M
Annual revenue covered
Originators in Cytomegalovirus Infection
Cliff calendar — next 15 years
6
29
2
33
Approved drugs ranked by patent estate
| Drug | Originator | Active patents | Avg vuln | Revenue | First cliff |
|---|---|---|---|---|---|
|
Prevymis
LETERMOVIR
|
Merck & Co. | 8 | 27 | $978M | 2029-01-18 |
Most attackable patents
| Patent | Drug | Type | Vuln | Expiry |
|---|---|---|---|---|
| 10603384 | Prevymis | formulation | 42 | 2033-02-28 |
| 10603384 | Prevymis | formulation | 42 | 2033-02-28 |
| RE46791 | Prevymis | composition of matter | 30 | 2029-01-18 |
| RE46791 | Prevymis | composition of matter | 30 | 2029-01-18 |
| RE46791 | Prevymis | composition of matter | 17 | 2029-01-18 |
| RE46791 | Prevymis | composition of matter | 17 | 2029-01-18 |
| RE46791 | Prevymis | composition of matter | 17 | 2029-01-18 |
| RE46791 | Prevymis | composition of matter | 17 | 2029-01-18 |
Strongest defences
| Patent | Drug | Type | Vuln | Expiry |
|---|---|---|---|---|
| RE46791 | Prevymis | composition of matter | 17 | 2029-01-18 |
| RE46791 | Prevymis | composition of matter | 17 | 2029-01-18 |
| RE46791 | Prevymis | composition of matter | 17 | 2029-01-18 |
| RE46791 | Prevymis | composition of matter | 17 | 2029-01-18 |
| RE46791 | Prevymis | composition of matter | 30 | 2029-01-18 |
| RE46791 | Prevymis | composition of matter | 30 | 2029-01-18 |
| 10603384 | Prevymis | formulation | 42 | 2033-02-28 |
| 10603384 | Prevymis | formulation | 42 | 2033-02-28 |
Related
- Cytomegalovirus Infection — full disease profile
- AI Patent Landscape Report — type "cytomegalovirus infection" for an AI exec memo
- Company Patent Rankings
- Biosimilar Opportunity Scanner